Side Effects

Semaglutide Side Effects: The Complete Guide for 2026

Q: What are the most common side effects of semaglutide?

The most common side effects are gastrointestinal: nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%) at the 2.4mg weight-management dose per STEP 1 trial. Most are mild to moderate and improve significantly within 4–8 weeks at each dose level.

Q: How long do semaglutide side effects last?

Most GI side effects are worst during the first 2–4 weeks at each new dose and improve as the body adapts. By the time patients have been on their target dose for 8+ weeks, the majority of acute GI symptoms have resolved. Each dose increase can temporarily reset symptoms.

Q: Does semaglutide cause hair loss?

Hair loss (alopecia) was reported by about 3% of patients on semaglutide vs 1% on placebo. This is almost always telogen effluvium — temporary shedding caused by rapid weight loss, not by the drug itself. It typically resolves within 6–12 months while continuing treatment.

Q: Does semaglutide cause cancer?

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies. However, after 5+ years of use and the SELECT trial (17,604 patients), no confirmed increase in thyroid cancer in humans has been found. It is contraindicated in patients with a history of medullary thyroid carcinoma or MEN2.

Q: What are the long-term side effects of semaglutide?

The SELECT trial (3.4-year median follow-up) found no new long-term side effects and showed a 20% reduction in cardiovascular events. GI side effects generally improved over time. Known long-term considerations include gallbladder health and potential impacts on muscle mass with sustained weight loss.

Sarah ChenLead Health Editor

Reviewed by Dr. James Okafor, PharmDPharmD

Updated March 29, 2026

Fact Checked

Every semaglutide side effect explained with clinical trial data. Common GI effects, rare serious risks, long-term safety, hair loss, cancer concerns — and how to manage them.

Key Takeaways

STEP 1 trial: nausea 44.2%, diarrhea 31.5%, vomiting 24.8%, constipation 24.2% at 2.4mg.
Hair loss (alopecia) reported by ~3% on semaglutide vs ~1% on placebo; it is telogen effluvium from weight loss.
Wegovy HD 7.2mg: dysesthesia (skin tingling/numbness) in 18.9% of patients vs 4.9% at 2.4mg.
Gallbladder events occurred in 1.6% of semaglutide patients vs 0.7% on placebo in STEP 1.
SELECT trial (17,604 patients, up to 5 years) found no new long-term safety signals.

On this page

Find your match

Answer a few questions and we’ll match you with the right provider and medication.

Take the Quiz →

Free · 2 min · No signup required

Semaglutide Side Effects: The Complete Guide for 2026

Medical disclaimer: This guide is for informational purposes only and does not constitute medical advice. Always consult your prescribing healthcare provider before making changes to your medication regimen. If you experience severe or concerning side effects, contact your doctor or seek emergency care.

Semaglutide is the most widely prescribed GLP-1 receptor agonist in the world. Sold under brand names including Ozempic (type 2 diabetes), Wegovy (weight management), Rybelsus (oral, diabetes), and the recently approved Wegovy HD (7.2mg, weight management), it has helped millions of patients lose significant weight and improve cardiometabolic health.

It also causes side effects in the majority of patients — and those side effects are the number one reason people hesitate to start treatment, struggle during dose escalation, or stop taking it altogether.

This guide is different from the vague lists you will find elsewhere. We break down every documented semaglutide side effect using actual clinical trial data — primarily from the STEP program, the SELECT cardiovascular outcomes trial, and the STEP UP trial for the new 7.2mg dose. You will find specific frequencies, realistic timelines, management strategies, and honest assessments of where the data is strong and where uncertainty remains.

Quick Reference: Semaglutide Side Effects at a Glance

This table covers injectable semaglutide at the standard 2.4mg weight-management dose, based on the STEP 1 trial (n=1,961, 68 weeks).

Very Common (>10% of patients)

Side Effect	Frequency (Semaglutide)	Frequency (Placebo)	Typical Severity	Usual Duration
Nausea	44.2%	17.8%	Mild to moderate	2–8 weeks per dose level
Diarrhea	31.5%	16.2%	Mild	Intermittent, improves over weeks
Vomiting	24.8%	6.4%	Mild to moderate	1–4 weeks per dose level
Constipation	24.2%	11.1%	Mild	Variable, may persist
Headache	14.3%	12.6%	Mild	First few weeks
Abdominal pain	12.0%	7.9%	Mild	Intermittent

Common (1–10% of patients)

Side Effect	Frequency (Semaglutide)	Frequency (Placebo)	Typical Severity	Usual Duration
Dyspepsia (indigestion)	9.2%	4.6%	Mild	Weeks
Fatigue	6.9%	4.2%	Mild	First few weeks
Dizziness	6.9%	4.0%	Mild	Transient
Abdominal distension	6.5%	3.0%	Mild	Variable
Eructation (belching)	5.7%	1.5%	Mild	Variable
Flatulence	5.6%	3.5%	Mild	Variable
GERD / acid reflux	4.9%	2.5%	Mild to moderate	May persist
Injection site reactions	3.2%	2.8%	Mild	Minutes to hours
Hair loss (alopecia)	3.0%	0.9%	Mild to moderate	6–12 months
Gallbladder events	1.6%	0.7%	Serious if symptomatic	Requires treatment

Uncommon (<1% of patients)

Side Effect	Frequency	Typical Severity	Notes
Acute pancreatitis	~0.2%	Serious	Requires hospitalization
Acute kidney injury	Rare	Serious	Usually dehydration-related
Allergic reactions	Rare	Variable	Anaphylaxis extremely rare
Increased heart rate	~3 bpm average increase	Usually not clinically significant	Persistent but modest

Rare but Serious (Boxed Warning)

Side Effect	Notes
Thyroid C-cell tumors	Boxed warning based on rodent studies; no confirmed human signal in 5+ years of data. Contraindicated in patients with personal/family history of MTC or MEN2.

Common GI Side Effects: The Big Four

Gastrointestinal side effects dominate the semaglutide experience. They occur because the drug slows gastric emptying, alters gut motility, and acts on nausea centers in the brainstem. Understanding each one individually — including how to manage it — is critical to staying on treatment long enough to see results.

Nausea (44.2%)

Nausea is the most frequently reported side effect of semaglutide. In the STEP 1 trial, 44.2% of patients on the 2.4mg dose experienced nausea compared to 17.8% on placebo.

The good news: in the vast majority of cases, it was rated as mild to moderate. Only 1.6% of patients discontinued treatment due to nausea alone.

Management strategies:

Eat smaller, more frequent meals — large meals overwhelm the already slowed stomach
Avoid high-fat, greasy, and fried foods during the first weeks at each dose
Eat slowly and stop when you first feel satisfied, not full
Stay hydrated — dehydration worsens nausea
Bland, room-temperature foods (crackers, toast, rice) are easier to tolerate during flare-ups
Ginger (tea, chews, or supplements) has evidence supporting its antiemetic effect
Talk to your prescriber about ondansetron (Zofran) if nausea is significantly impacting your quality of life

For a full breakdown of evidence-based nausea management, see our GLP-1 Nausea Management Guide.

Diarrhea (31.5%)

Diarrhea affected 31.5% of semaglutide patients in the STEP 1 trial versus 16.2% on placebo. It tends to be intermittent rather than constant, and many patients describe it as looser stools rather than true watery diarrhea.

Management strategies:

Monitor hydration and electrolytes — this matters more than most patients realize
Reduce sugar alcohols, artificial sweeteners, and high-fiber foods temporarily
Avoid caffeine and alcohol during acute episodes
Loperamide (Imodium) is safe to use as needed for symptomatic relief
Probiotics may help some patients, though evidence is mixed
Track whether episodes correlate with specific foods — many patients identify personal triggers

Vomiting (24.8%)

Vomiting was reported by 24.8% of patients on semaglutide in STEP 1 versus 6.4% on placebo. Like nausea, it is most common during dose escalation and typically resolves within a few weeks at a stable dose.

Management strategies:

Do not eat large meals — this is the single most important adjustment
If vomiting is frequent, request a slower dose titration from your prescriber
Sip clear fluids — small amounts frequently, rather than gulping large volumes
Prescription antiemetics (ondansetron, promethazine) are appropriate for persistent vomiting
Contact your doctor if you cannot keep fluids down for 24+ hours — dehydration and kidney injury are real risks

Constipation (24.2%)

Constipation affected 24.2% of semaglutide patients versus 11.1% on placebo. Semaglutide slows gut transit time, which can harden stools and reduce bowel frequency. Unlike nausea and vomiting, constipation may persist rather than resolving on its own.

Management strategies:

Increase water intake substantially — at least 64 oz daily, more if active
Fiber supplementation (psyllium husk, methylcellulose) — increase gradually to avoid bloating
Regular physical activity promotes gut motility
Osmotic laxatives (MiraLAX/polyethylene glycol) are first-line for GLP-1-related constipation
Magnesium citrate at bedtime can help both constipation and sleep
Avoid stimulant laxatives (senna, bisacodyl) as a daily solution — they can cause dependence

For detailed evidence-based protocols, see our GLP-1 Constipation Guide.

How Long Do Semaglutide Side Effects Last?

This is one of the most important questions patients ask — and the answer is more nuanced than "a few weeks." Side effects follow a predictable pattern tied to dose escalation, and understanding the timeline helps patients push through the hardest periods.

The General Timeline

Weeks 1–2 (starting dose, 0.25mg): Most patients notice minimal side effects at the starting dose. Some experience mild nausea or reduced appetite. This is the honeymoon period.

Weeks 3–4 (first dose increase to 0.5mg): Side effects typically intensify with the first dose increase. Nausea becomes more noticeable. This is when many patients first feel the drug "working."

Weeks 5–8 (stabilization at 0.5mg): The body adjusts. Most patients see significant improvement in nausea and other GI symptoms by week 6–8 at a given dose. This is when you start to understand the pattern.

Each subsequent dose increase (1.0mg, 1.7mg, 2.4mg): Each increase can temporarily reset the clock on GI side effects. The key word is "temporarily." Most patients find that symptoms at each new dose are milder than they were at the previous escalation, because the body has partially adapted.

Weeks 16–20 (reaching maintenance dose): By the time most patients stabilize at their target dose, the acute GI side effects have largely resolved. STEP 1 extension data shows that the majority of nausea and vomiting episodes occur during the first 20 weeks of treatment.

Months 6–12 and beyond: Persistent GI symptoms at this stage are uncommon. Patients who still experience significant nausea or vomiting after 6+ months at a stable dose should discuss alternative medications or dose adjustments with their prescriber.

What the Long-Term Data Shows

In the STEP 5 trial (2-year data), the rate of ongoing GI adverse events decreased substantially after the dose-escalation phase. By year two, the GI side effect profile of semaglutide was much closer to placebo than it was during the first six months. This is consistent with physiological adaptation to GLP-1 receptor activation.

The practical takeaway: if you can get through the first 4–8 weeks at each dose level, side effects are very likely to improve.

Semaglutide vs Other GLP-1 Side Effects

Patients often ask whether switching medications would mean fewer side effects. The short answer: all GLP-1 receptor agonists share a similar core side effect profile, but the rates and relative severity differ.

Semaglutide vs Tirzepatide

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. In head-to-head context (not direct comparison trials):

Side Effect	Semaglutide 2.4mg (STEP 1)	Tirzepatide 15mg (SURMOUNT-1)
Nausea	44.2%	33.3%
Diarrhea	31.5%	23.0%
Vomiting	24.8%	12.2%
Constipation	24.2%	11.7%

Tirzepatide generally has lower reported GI side effect rates at its highest approved doses, despite producing greater average weight loss. However, these numbers come from different trials with different populations, so direct comparison has limitations.

For a detailed head-to-head analysis, see our Zepbound vs Wegovy Comparison.

Semaglutide vs Orforglipron (Oral, Non-Peptide)

Orforglipron is the first oral non-peptide GLP-1 agonist. Early clinical data suggests a GI side effect profile broadly similar to injectable semaglutide, though nausea rates may be somewhat lower. Data is still maturing.

For a comprehensive medication-by-medication breakdown, see our GLP-1 Side Effects by Medication Guide.

Wegovy HD (7.2mg) — New Side Effect Data

In late 2025, the FDA approved Wegovy HD — semaglutide at 7.2mg, three times the original maximum dose of 2.4mg. The STEP UP trial provided the first safety data at this dose, and there are meaningful differences from the standard dose.

Key Findings from STEP UP

Weight loss: 20.7% average body weight reduction (vs 14.4% at 2.4mg in the same trial)
GI side effects: Higher rates across the board, as expected with a higher dose
Dysesthesia (unusual skin sensations): 18.9% in the 7.2mg group vs 4.9% in the 2.4mg group. This is a new and notable finding — a side effect that appears to be more specific to the higher dose rather than just more frequent.
Discontinuation due to adverse events: Higher than at 2.4mg, though the majority of patients still tolerated the dose

The dysesthesia finding is particularly important because it represents a qualitatively different side effect, not just "more nausea." Patients describe it as tingling, numbness, burning, or prickling sensations, typically in the extremities. It resolved after discontinuation in most cases but was persistent during treatment. If you're weighing the higher-dose semaglutide option against tirzepatide, our Wegovy HD vs Zepbound comparison covers the side effect trade-offs in detail.

For the full analysis, see our Wegovy HD (Semaglutide 7.2mg) Guide.

Compounded Semaglutide Side Effects

Compounded semaglutide — custom-formulated by compounding pharmacies — has been widely available through telehealth platforms, often at lower prices than branded versions. However, the side effect profile carries additional considerations.

What's Different About Compounded Formulations

Less clinical data: Compounded semaglutide has not gone through the same rigorous clinical trials as branded Ozempic or Wegovy. This means we have less precise data on side effect rates at specific doses.

Variable formulations: Compounded products may include additional ingredients such as:

Cyanocobalamin (vitamin B12): Added to some compounded formulations to address the B12 depletion that can occur with GLP-1 treatment. Side effects of the cyanocobalamin component itself are rare but can include injection site pain, itching, or mild GI symptoms. There is no large-scale clinical data on the combined semaglutide/cyanocobalamin formulation.
L-carnitine, NAD+, or other additives: Some compounders add ingredients without robust evidence for benefit or well-characterized interaction profiles.

Quality and consistency concerns: The FDA has issued multiple warning letters to compounding pharmacies over sterility failures, incorrect potency, and impurities. This is not a theoretical concern — contaminated injectable products can cause serious infections and injection site reactions beyond what branded semaglutide would produce.

Dosing variability: Without the standardized pen delivery systems used by Novo Nordisk, compounded semaglutide administered via vial and syringe may result in less consistent dosing, which can lead to more unpredictable side effect patterns.

For a thorough review of compounding options, risks, and the current regulatory landscape, see our GLP-1 Compounding Alternatives Guide.

Serious Side Effects (Rare but Important)

While the majority of semaglutide side effects are GI-related and self-limiting, several rare but serious adverse events require awareness.

Acute Pancreatitis (~0.2%)

Pancreatitis was reported in approximately 0.2% of patients on semaglutide in clinical trials versus a similar or slightly lower rate on placebo. Symptoms include severe, persistent abdominal pain radiating to the back, often with nausea and vomiting.

Semaglutide should be discontinued if pancreatitis is confirmed
Patients with a history of pancreatitis should discuss risks carefully with their prescriber
The absolute risk is low, but the condition is serious when it occurs

Gallbladder Disease (1.6%)

Gallbladder events — including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) — occurred in 1.6% of semaglutide patients versus 0.7% on placebo in STEP 1. Rapid weight loss is a well-known risk factor for gallstone formation regardless of the method, so this is likely a consequence of the weight loss itself rather than a direct drug effect.

Symptoms include upper right abdominal pain, especially after meals
Ultrasound is the standard diagnostic tool
Some cases require cholecystectomy (gallbladder removal)

Thyroid C-Cell Tumors (Boxed Warning)

Semaglutide carries a boxed warning — the FDA's most serious warning — regarding the risk of thyroid C-cell tumors. This warning is based on rodent studies in which semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice.

Important context:

Rodent thyroid C-cells have GLP-1 receptors at much higher density than human thyroid C-cells
After 5+ years of real-world use and the large SELECT trial (17,604 patients over 3.4 years median follow-up), there has been no confirmed signal of increased thyroid cancer in humans
Semaglutide is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
For patients without these risk factors, the available human data is reassuring — but ongoing surveillance continues

For a detailed analysis, see our GLP-1 and Thyroid Cancer Risk Guide.

Acute Kidney Injury

Acute kidney injury has been reported in patients taking semaglutide, though it is almost always secondary to dehydration from severe vomiting or diarrhea rather than a direct nephrotoxic effect.

Maintaining adequate hydration is critical, especially during dose escalation
Patients with pre-existing kidney disease should have renal function monitored — notably, emerging research suggests GLP-1s may offer kidney-protective benefits for these patients
If you cannot keep fluids down, contact your prescriber immediately

Allergic Reactions

Serious allergic reactions (anaphylaxis, angioedema) are extremely rare but have been reported. Signs include swelling of the face, lips, tongue, or throat; difficulty breathing; severe rash; and rapid heartbeat. This requires emergency medical attention.

Long-Term Safety: What 5+ Years of Data Shows

The most comprehensive long-term safety data for semaglutide comes from the SELECT trial — a cardiovascular outcomes study that followed 17,604 patients with overweight or obesity and established cardiovascular disease for a median of 3.4 years (with some patients followed for over 5 years).

Key Long-Term Findings

20% reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — in the semaglutide group versus placebo
No new safety signals emerged during extended follow-up
GI side effects diminished over time, consistent with physiological adaptation
No increase in thyroid cancer, pancreatitis, or other rare serious events beyond what was seen in shorter trials
Heart rate increased by approximately 3 bpm on average — persistent but not associated with adverse cardiovascular outcomes

The SELECT results transformed the risk-benefit calculus for semaglutide by demonstrating not just the absence of long-term harm but a significant cardiovascular benefit.

What We Still Don't Know

Effects of 10+ years of continuous use at weight-management doses
Whether cardiovascular benefits persist after discontinuation
Long-term impact on bone density with sustained weight loss
Effects across more diverse populations (SELECT was predominantly white and male)

For the complete long-term safety analysis, see our GLP-1 Long-Term Safety Data Guide.

Semaglutide and Hair Loss

Hair loss is one of the side effects that generates the most concern online — particularly on Reddit and social media — even though it affects a relatively small percentage of patients.

What the Data Shows

In STEP 1, alopecia (hair loss) was reported by 3.0% of patients on semaglutide versus 0.9% on placebo. In STEP 5 (2-year data), the rate was 3.2% versus 1.1%.

Why It Happens

The hair loss associated with semaglutide is almost certainly telogen effluvium — a temporary shedding caused by rapid weight loss and caloric deficit, not a direct pharmacological effect of the drug. Telogen effluvium occurs when a physical stressor (surgery, illness, crash dieting, rapid weight loss) pushes a larger-than-normal percentage of hair follicles into the resting (telogen) phase simultaneously. Two to four months later, those hairs shed.

Key points:

The degree of hair loss correlates with the rate and amount of weight loss, not the semaglutide dose specifically
Tirzepatide at higher doses (which produces more weight loss) shows higher hair loss rates (up to 5.7% in SURMOUNT-1)
Bariatric surgery patients experience similar or higher rates of hair shedding
Hair loss is almost always temporary, resolving within 6–12 months even if treatment continues
Adequate protein intake (at least 60–80g daily) and micronutrient status (iron, zinc, biotin, vitamin D) are the most effective preventive strategies

For the full guide including management protocols, see our GLP-1 Hair Loss Guide.

Semaglutide and Cancer

The cancer question — particularly around thyroid cancer — is among the most anxiety-inducing topics for patients considering semaglutide. Here is what the data actually shows.

The Rodent Signal

GLP-1 receptor agonists, including semaglutide, cause thyroid C-cell tumors (including medullary thyroid carcinoma) in rodents at clinically relevant exposures. This finding led to the boxed warning on all GLP-1 medications.

The Human Data

After more than five years of widespread use and multiple large clinical trials:

No confirmed increase in medullary thyroid carcinoma (MTC) in humans has been observed
The SELECT trial (17,604 patients, 3.4 years median follow-up) found no signal for any cancer type
Population-based observational studies have not identified an increased risk of thyroid cancer in GLP-1 users
A 2023 meta-analysis published in The Lancet Diabetes & Endocrinology found no association between GLP-1 receptor agonists and thyroid cancer in humans

The Biological Explanation

Human thyroid C-cells express far fewer GLP-1 receptors than rodent C-cells. The rodent thyroid is physiologically different from the human thyroid in ways that are directly relevant to this concern. Most endocrinologists believe the rodent findings do not translate to humans, though the FDA appropriately maintains the warning given the theoretical risk.

The Contraindication

Regardless of the reassuring human data, semaglutide remains absolutely contraindicated in:

Patients with a personal history of medullary thyroid carcinoma
Patients with a family history of MTC
Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

If you have any of these conditions, GLP-1 medications are not appropriate for you. Period.

For a balanced, in-depth analysis, see our GLP-1 and Thyroid Cancer Risk Guide.

Oral vs Injectable Semaglutide Side Effects

Semaglutide is available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations. The oral form uses an absorption enhancer (SNAC) to survive the stomach and reach the bloodstream. This creates some differences in the side effect profile.

Shared Side Effects

The core GI side effects — nausea, diarrhea, vomiting, constipation — are present with both formulations at similar rates when doses are equivalent in terms of systemic exposure.

Unique to Oral Semaglutide

Erosive esophagitis: Oral semaglutide tablets must be taken on an empty stomach with no more than 4 oz of water, followed by 30 minutes of fasting. If the tablet doesn't reach the stomach (e.g., lying down after taking it) or dissolves in the esophagus, it can cause esophageal irritation or erosive esophagitis.

This risk is effectively eliminated by following the dosing instructions carefully
Patients with known esophageal conditions (Barrett's esophagus, strictures) should discuss this risk with their prescriber

Dosing inconvenience and food interactions: The strict fasting requirement can cause GI discomfort if patients eat too soon after taking the pill, as the absorption enhancer may irritate the stomach lining when food is present.

For a full comparison, see our Oral vs Injectable Semaglutide Comparison.

When to Call Your Doctor: Red Flags Checklist

Most semaglutide side effects are manageable. But some symptoms require immediate medical attention. Contact your healthcare provider or seek emergency care if you experience any of the following:

Severe, persistent abdominal pain that radiates to your back (possible pancreatitis)
Persistent vomiting lasting more than 24 hours, or inability to keep any fluids down
Signs of jaundice — yellowing of the skin or eyes (possible gallbladder or liver issue)
Signs of severe allergic reaction — swelling of face, lips, tongue, or throat; difficulty breathing; severe rash
A lump or swelling in your neck, hoarseness, or difficulty swallowing (thyroid concern)
Signs of severe dehydration — dark urine, dizziness, rapid heartbeat, confusion
Significant changes in vision (diabetic retinopathy can be affected by rapid blood sugar changes)
Severe, unexplained diarrhea with signs of dehydration
Symptoms of kidney injury — decreased urination, swelling in legs/feet, unusual fatigue
Suicidal thoughts or significant mood changes (rare, under ongoing FDA surveillance)

When in doubt, call your doctor. These medications are generally safe, but the rare serious events require prompt action to ensure good outcomes.

Frequently Asked Questions

Q: What are the most common side effects of semaglutide?

A: The most common side effects are gastrointestinal: nausea (44%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%). These rates come from the STEP 1 clinical trial at the 2.4mg weight-management dose. Most are mild to moderate and improve significantly within 4–8 weeks at each dose level.

Q: How long do semaglutide side effects last?

A: Most GI side effects are worst during the first 2–4 weeks at each new dose level and improve as your body adapts. The standard dose-escalation schedule takes about 16–20 weeks to reach the full 2.4mg dose. By the time patients have been on their target dose for 8+ weeks, the majority of acute GI symptoms have resolved. Each dose increase can temporarily reset side effects, but they tend to be milder with each subsequent escalation.

Q: Does semaglutide cause hair loss?

A: Hair loss (alopecia) was reported by about 3% of patients on semaglutide in clinical trials, compared to about 1% on placebo. This is almost always telogen effluvium — a temporary shedding caused by rapid weight loss, not by the drug directly. It typically begins 2–4 months after significant weight loss and resolves within 6–12 months. Adequate protein and micronutrient intake significantly reduce the risk. See our GLP-1 Hair Loss Guide for detailed prevention strategies.

Q: Does semaglutide cause cancer?

A: Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies. However, after 5+ years of real-world use and the large SELECT trial (17,604 patients), there has been no confirmed increase in thyroid cancer or any other cancer in humans. The biological differences between rodent and human thyroid cells explain why the rodent findings may not translate. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Q: Are compounded semaglutide side effects different from branded versions?

A: Compounded semaglutide should have similar pharmacological side effects to branded versions if the active ingredient is the same. However, compounded formulations carry additional risks related to quality control, sterility, and dosing consistency. Formulations that include additives like cyanocobalamin (vitamin B12) may cause additional injection site reactions or mild GI effects. The FDA has issued warnings about some compounding pharmacies regarding contamination and potency issues.

Q: How do semaglutide side effects compare to tirzepatide (Zepbound)?

A: In separate clinical trials, tirzepatide generally showed lower rates of GI side effects than semaglutide at their respective highest approved doses — despite tirzepatide producing greater average weight loss. For example, nausea was reported by 33.3% of patients on tirzepatide 15mg versus 44.2% on semaglutide 2.4mg. However, these figures come from different trials with different patient populations, so direct comparison has limitations. See our Zepbound vs Wegovy Comparison for the full analysis.

Q: What are the long-term side effects of semaglutide?

A: The longest controlled data comes from the SELECT trial (median 3.4 years, up to 5+ years for some patients). No new long-term side effects emerged beyond those identified in shorter trials. GI side effects generally improved over time. The trial demonstrated a 20% reduction in cardiovascular events, suggesting long-term cardiovascular benefit. Known long-term considerations include potential impacts on gallbladder health, muscle mass, and bone density with sustained weight loss. See our GLP-1 Long-Term Safety Data Guide.

Q: What side effects are unique to the new Wegovy HD 7.2mg dose?

A: The STEP UP trial revealed that dysesthesia (unusual skin sensations like tingling, numbness, or burning) occurred in 18.9% of patients on the 7.2mg dose versus 4.9% on 2.4mg. This appears to be a dose-dependent side effect that is qualitatively different from the standard GI effects. All standard GI side effects also occurred at higher rates at 7.2mg. See our Wegovy HD Guide for complete STEP UP trial data, and our Wegovy HD vs Zepbound comparison for how this high-dose semaglutide stacks up against tirzepatide.

Q: What do people on Reddit report about semaglutide side effects?

A: Patient-reported experiences on forums like Reddit are broadly consistent with clinical trial data — nausea, appetite changes, and GI symptoms dominate the discussion. Reddit users frequently emphasize the importance of slow dose titration, staying hydrated, and eating small meals. Some common themes not well-captured in trial data include taste changes, food aversions, increased sensitivity to certain smells, and what patients describe as "sulfur burps." While these anecdotal reports are valuable for setting expectations, they are subject to reporting bias — patients with strong reactions (positive or negative) are more likely to post.

Q: Should I stop semaglutide if I'm having side effects?

A: In most cases, no. The majority of semaglutide side effects are temporary and manageable. Before stopping, talk to your prescriber about strategies like slowing your dose escalation, temporarily reducing your dose, adjusting meal timing and composition, or adding supportive medications (antiemetics, laxatives). Stopping abruptly is rarely necessary unless you experience serious side effects like severe pancreatitis symptoms, allergic reactions, or inability to maintain hydration. Your prescriber can help you weigh the side effect burden against the clinical benefits.

Sources

Sarah Chen

Lead Health Editor

Sarah covers telehealth and digital health access. She has spent 8 years in health journalism, previously writing for health policy publications. She leads editorial at Telehealth Ally.

Medically Reviewed By

Dr. James Okafor, PharmD

Dr. Okafor is a licensed pharmacist who reviews medication guides and dosing content for clinical accuracy. He has 12 years of experience in clinical pharmacy.

Related Comparisons

Compounded Semaglutide Providers 2026: Who Still Offers It, Pricing & Safety

Complete roundup of every telehealth provider still offering compounded semaglutide in 2026 — pricing comparison, safety considerations, FDA enforcement status, and when to switch to brand.

Compounded Semaglutide vs Brand Wegovy: Is It Worth It?

Compounded semaglutide vs brand Wegovy comparison covering safety, FDA regulation, cost ($149 vs $1,349/mo), efficacy considerations, and who should choose each option.

Oral Semaglutide (Rybelsus) vs Injectable: Pros and Cons

Oral semaglutide (Rybelsus) vs injectable Wegovy comparison covering weight loss efficacy, dosing differences, convenience, cost, side effects, and who should choose each form.

Semaglutide Side Effects: The Complete Guide for 2026

Key Takeaways

Semaglutide Side Effects: The Complete Guide for 2026

Quick Reference: Semaglutide Side Effects at a Glance

Very Common (>10% of patients)

Common (1–10% of patients)

Uncommon (<1% of patients)

Rare but Serious (Boxed Warning)

Common GI Side Effects: The Big Four

Nausea (44.2%)

Diarrhea (31.5%)

Vomiting (24.8%)

Constipation (24.2%)

How Long Do Semaglutide Side Effects Last?

The General Timeline

What the Long-Term Data Shows

Semaglutide vs Other GLP-1 Side Effects

Semaglutide vs Tirzepatide

Semaglutide vs Orforglipron (Oral, Non-Peptide)

Wegovy HD (7.2mg) — New Side Effect Data

Key Findings from STEP UP

Compounded Semaglutide Side Effects

What's Different About Compounded Formulations

Serious Side Effects (Rare but Important)

Acute Pancreatitis (~0.2%)

Gallbladder Disease (1.6%)

Thyroid C-Cell Tumors (Boxed Warning)

Acute Kidney Injury

Allergic Reactions

Long-Term Safety: What 5+ Years of Data Shows

Key Long-Term Findings

What We Still Don't Know

Semaglutide and Hair Loss

What the Data Shows

Why It Happens

Semaglutide and Cancer

The Rodent Signal

The Human Data

The Biological Explanation

The Contraindication

Oral vs Injectable Semaglutide Side Effects

Shared Side Effects

Unique to Oral Semaglutide

When to Call Your Doctor: Red Flags Checklist

Frequently Asked Questions

Sources

Related Comparisons

Compounded Semaglutide Providers 2026: Who Still Offers It, Pricing & Safety

Compounded Semaglutide vs Brand Wegovy: Is It Worth It?

Oral Semaglutide (Rybelsus) vs Injectable: Pros and Cons

More Guides

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Best Oral GLP-1 Options in 2026: Every Pill Compared

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Best BPC-157 Telehealth Providers 2026: Complete Guide

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?

CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect

CagriSema Launch Day Patient Guide: What to Do Now That It's Here

CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide

CagriSema FDA Decision Guide: What to Expect and How to Prepare

CagriSema: What Patients Need to Know While the FDA Decision Drags On

CagriSema Side Effects: What Clinical Trials Show About Safety and Tolerability

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price